NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/30/2026
Back to search
Official data from USPTO
TARGED TARGETED ENZYME DELIVERY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
06/30/2026
Trademark type
Combined
Nice classes
5, 42
Filing date
08/22/2025
Registration date
06/30/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/30/2026
Last transaction
06/30/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
24
Owner location
NL
Examiner
HUDSON, TAMARA BREE
Law office
L40
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the word "TARGED" in stylized font wherein the letters "TARG" are in aqua green and the letters "ED" are in dark green, with a dark green arrow forming the middle arm of the "E"; below this word is the wording "TARGETED ENZYME DELIVERY" in stylized grey font.
Holders and representatives
Holders
TargED Biopharmaceuticals B.V.
Representatives
Lindsay M.R. Jones
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of diseases associated with thrombosis; medical preparations for the treatment of diseases associated with thrombosis; dietary supplements for medical purposes; medicinal herbs and medicinal herbal extracts; drugs for medical purposes for the treatment of diseases associated with thrombosispharmaceutical preparations for the prevention and treatment of diseases associated with thrombosis; pharmaceutical preparations being antithrombotic agents; thrombolytic drugs; pharmaceutical preparations being coagulation inhibitors; anticoagulants; pharmaceutical preparations in the nature of platelet aggregation inhibitors; pharmaceutical preparations in the nature of hemostatic agents; pharmaceutical preparationsblood thinners for medical use; therapeutic compounds for diseases associated with thrombosis; pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for blood clotting disorders; injectable or intravenous medicinal solutions for thrombosis-related treatment; medicinal preparations for the treatment of deep vein thrombosis (DVT); medicinal preparations for pulmonary embolism (PE) management; preclinical or clinical trial medicines for thrombosis-related treatment research; pharmaceuticals for vascular diseases
Class 42
Scientific and technological servicesresearch and design in the field of medicine and pharmaceuticals; research and development services in the field of medicine and pharmaceuticals; scientific research in the nature of conducting laboratory and clinical testing for others; biotechnology research services; pharmaceutical research services; medical and scientific laboratory services; medical research and development services; research and development in the field of thrombosis treatment; pharmaceutical and biotechnology research for antithrombotic drugs; scientific research in the nature of conducting preclinical and clinical trials for others in the field of drugs for diseases associated with thrombosis; d r u g discovery services related to thrombosis; development of biopharmaceuticals for cardiovascular diseases; scientific research in the field of platelet aggregation inhibitors; consultancy services in pharmaceutical research and development; conducting scientific studies related to thrombosis-related and blood clotting disorders; scientific research in the nature of conducting clinical trials for others in the field of thrombosis-related drugs and therapies; design and development of drug efficacy studies for treatment of diseases associated with thrombosis; genetic research and molecular biology research services related to thrombosis; technical data analysis of scientific research and providing temporary use of onlinenon-downloadable computer software for use in modeling in the field of treatment of diseases associated with thrombosis; laboratory research services for thrombosis-related diagnosis and testing; research services related to anticoagulation therapy; research in personalized medicine for patients of diseases associated with thrombosis patients; quality assessmentreference material certification services being the testinganalysis and evaluation of the goods of others to determine conformity with certification standards in the field of treatment of diseases associated with thrombosis treatment; research and development services for biotechnological solutions for diseases associated with thrombosis; scientific advisory and consultation services in thrombosis-related research
Publications
History of USPTO decisions and trademark events.
22 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/30/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/12/2026
PUBO
PUBLISHED FOR OPPOSITION
05/12/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/06/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/14/2026
XAEC
EXAMINER'S AMENDMENT ENTERED
04/14/2026
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/14/2026
GNEA
EXAMINERS AMENDMENT E-MAILED
04/14/2026
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/14/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/14/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/14/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/14/2026
RFNT
REFUSAL PROCESSED BY IB
02/26/2026
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/12/2026
RFRR
REFUSAL PROCESSED BY MPU
02/11/2026
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/15/2026
CNRT
NON-FINAL ACTION WRITTEN
01/14/2026
DOCK
ASSIGNED TO EXAMINER
01/07/2026
MAFR
APPLICATION FILING RECEIPT MAILED
11/28/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/28/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/27/2025
Continuous trademark protection
Get notified about every new filing that threatens TARGED TARGETED ENZYME DELIVERY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.